Alzinova is developing the vaccine ALZ-101, which targets toxic amyloid-beta oligomers – a key driver of Alzheimer’s disease. In the Phase Ib study was completed earlier this year, the candidate demonstrated good safety, tolerability and a durable immune response, along with signs of stabilization in cognitive function and the biomarker NFL. Preparations are currently underway for a planned global Phase II study in collaboration with the contract research organization Worldwide Clinical Trials.
FDA decisions strengthens both pace and credibility
During the third quarter, Alzinova obtained both FDA Investigational New Drug (IND) approval and Fast Track designation for ALZ-101, giving the company the green light to initiate its Phase II study in the U.S. and enabling more frequent communication with the agency as well as a more efficient review process. According to CEO Tord Labuda, these achievements confirm the quality of the company’s research and strengthen ALZ-101’s commercial positioning.
New scientific findings to be presented at CTAD
Next on the agenda, Alzinova will participate in Clinical Trials on Alzheimer’s Disease (CTAD) 2025, held December 1–4 in San Diego. The company has had two abstracts accepted for presentation, both based on data from the Phase Ib study with ALZ-101.
In parallel, Alzinova is finalizing a scientific manuscript summarizing the entire Phase Ib program, which will be submitted to a leading journal for publication. Together, these initiatives will further strengthen the data package ahead of the planned Phase II study. The long-term goal is to demonstrate that ALZ-101 can modulate disease progression in a way that sets it apart from today’s treatments.
Comments from the CEO
BioStock asked CEO Tord Labuda to comment on the company’s recent progress, the upcoming CTAD presentations, and preparations for the Phase II study.
What events during the third quarter do you consider most significant for Alzinova and its continued development?
– The third quarter strengthened our position in several key areas. The FDA’s decisions to grant both IND approval and Fast Track designation are major milestones from an external, independent authority, confirming the quality of our work and providing the framework to enter Phase II with clear direction and a more efficient regulatory path.
– On the financial side, the short-term loan has provided the flexibility we need at this stage. It allows us to move the business forward responsibly while continuing to focus on partnership discussions and securing the long-term financing required for Phase II. The study can only begin once financing is in place, and that remains a firm condition. Overall, we now stand on a solid scientific, regulatory and operational foundation as we prepare for the next step.
You will present two abstracts at CTAD in San Diego. What does it mean for Alzinova to participate, and what do you hope the audience will take away from the results?
– Presenting at CTAD is an important milestone for us. It is one of the most influential conferences in clinical Alzheimer’s research, bringing together world-leading experts from both industry and academia. For Alzinova, it’s an opportunity to highlight the strength of our Phase Ib program and to position ALZ-101 in an international context.
– We hope that the audience will recognize the strength of our Phase Ib data and the fact that ALZ-1 has a unique, oligomer-specific mechanism with significant disease-modifying potential. This profile sets the candidate apart from current treatments and makes the Phase II study particularly exciting.
You now have a clearer view of ALZ-101’s disease-modifying potential. How do you see the candidate’s position relative to today’s treatments?
– Unlike today’s treatments, which mainly focus on breaking down and removing existing amyloid plaques in the brain, ALZ-101 is designed to actively stimulate the patient’s own immune system against toxic amyloid-beta oligomers – early, disease-driving aggregates. Phase Ib data have shown that our candidate has a favorable safety profile, induces a selective and durable immune response, and shows a trend toward stabilization of cognitive function and biomarker levels, supporting a potentially disease-modifying effect.
– An important piece of support for our mechanism comes from new biomarker findings showing that naturally occurring antibodies (NAbs) against these oligomers have been identified in both healthy individuals and Alzheimer’s patients, but that levels are particularly high in healthy elderly people. This indicates an endogenous protective mechanism that ALZ-101 appears capable of inducing in Alzheimer’s patients. Our active vaccine concept therefore distinguishes ALZ-101 both in treatment principle and practical use compared with existing plaque-focused passive immunotherapies.
Partnerships are central to your strategy. How are discussions with potential partners progressing?
– Alzinova is in an intensive and productive phase, running several parallel initiatives to strengthen clinical development and deepen dialogues with potential partners. We clearly see growing recognition of our work. Interest in ALZ-101 is increasing, and we are active in numerous discussions focused on finding the right strategic match between our development plan and the needs and priorities of larger players in the field.
– Relationship-building takes time, which is a natural part of the process. What all our discussions have in common is transparency around our data. It is robust, clear and generates interest. Our current focus is on ensuring that we move forward with a partner who shares our scientific view and ambition for ALZ-101.
You recently attended BIO-Europe. What impact did those meetings have on your business development efforts and ongoing partnership discussions?
– At our current stage, direct and qualified dialogues with potential partners are crucial. BIO-Europe gave us the opportunity to hold in-depth meetings with companies actively seeking promising projects in neurodegenerative diseases – many of whom have followed our progress for some time. Most meetings focused on our Phase Ib data, and we experienced particularly strong interest in our findings on naturally occurring antibodies and their implications for our therapeutic approach. These discussions simply cannot be held at the same level without personal interaction.
– The event was valuable for deepening relationships already established. Being able to follow up on previous discussions, present new data points, and receive direct feedback on our development plan helps ensure we are on the right track in shaping a future partnership. Overall, the meetings strengthened both understanding of our mechanism and interest in ALZ-101’s potential – key factors for decisions ahead of the next phase.
What will be the most important milestones for Alzinova in the first half of 2026?
– During the first half of 2026, we will continue working toward two key objectives: advancing our partnership discussions and securing the financial conditions for Phase II. Our strategic direction remains clear – to ultimately establish a partnership with a company that shares our ambition for ALZ-101 and can contribute the resources needed to drive development forward.
– In parallel, we are continuing preparations for Phase II, with the goal of initiating the study once financing is secured and all quality requirements are met.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.